1. Home
  2. DCBO vs CTMX Comparison

DCBO vs CTMX Comparison

Compare DCBO & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

N/A

Current Price

$32.64

Market Cap

810.7M

Sector

N/A

ML Signal

N/A

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

N/A

Current Price

$2.01

Market Cap

716.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DCBO
CTMX
Founded
2016
2008
Country
Canada
United States
Employees
900
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
810.7M
716.9M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
DCBO
CTMX
Price
$32.64
$2.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
8
Target Price
★ $36.45
$12.38
AVG Volume (30 Days)
53.7K
★ 5.0M
Earning Date
11-06-2026
11-05-2026
Dividend Yield
★ 7.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
★ $76,201,000.00
Revenue This Year
$13.98
N/A
Revenue Next Year
$10.34
$36.55
P/E Ratio
★ $22.04
$22.58
Revenue Growth
★ N/A
N/A
52 Week Low
$14.39
$1.90
52 Week High
$33.19
$8.21

Technical Indicators

Market Signals
Indicator
DCBO
CTMX
Relative Strength Index (RSI) 69.52 38.96
Support Level $16.54 N/A
Resistance Level N/A $2.61
Average True Range (ATR) 1.47 0.19
MACD 0.11 -0.00
Stochastic Oscillator 89.76 24.04

Price Performance

Historical Comparison
DCBO
CTMX

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: